Voxilaprevir

• CAT Number: I010171
• CAS Number: 1535212-07-7
• Molecular Formula: C40H52F4N6O9S
• Molecular Weight: 868.943
• Purity: ≥95%
• Storage: Store at -20°C
• InChI: InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
• InChIKey: MZBLZLWXUBZHSL-FZNJKFJKSA-N
• SMILES: CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C

Voxilaprevir (CAT: I010171) is a hepatitis C virus (HCV) NS3/4A protease inhibitor that is used in combination with other antiviral agents for the treatment of chronic HCV infection. It works by inhibiting the NS3/4A protease enzyme, which is essential for the replication of the virus. Voxilaprevir is typically administered orally and has been shown to have high antiviral activity against all major HCV genotypes, including those that are resistant to other HCV drugs. It is generally well-tolerated and has a low risk of drug interactions, making it a useful addition to the treatment armamentarium for HCV infection.